摘要
急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是儿童最常见的血液恶性肿瘤,近年来儿童ALL患者的预后有了显著改善。然而对于复发/难治ALL患者,常规的化学治疗缓解率低,预后不佳。随着免疫疗法的兴起,针对ALL抗原相关的单克隆抗体和嵌合抗原受体T细胞等免疫治疗已被证实对ALL有效,显著改善复发/难治ALL患者的预后。
Acute lymphoblastic leukemia(ALL)is the most common hematologic malignancy in children.The prognosis of ALL in pediatric patients has significantly improved in recent years.However,for pediatric population with relapsed/refractory ALL,conventional chemotherapy has a low remission rate and provides no promising prognosis.With the emergence of immunotherapy,immunotherapies targeting ALL antigen-associated monoclonal antibodies and chimeric antigen receptor T cells have shown to be effective against ALL,significantly improving the prognosis in patients with relapsed/refractory ALL.In this article,we review the immunotherapy for ALL in children.
作者
彭思静
卢婕伦
王子成
曾晓珍
邹亚伟
PENG Sijing;LU Jielun;WANG Zicheng;ZENG Xiaozhen;ZOU Yawei(Department of Pediatrics,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;不详)
出处
《实用医学杂志》
CAS
北大核心
2022年第23期2903-2907,共5页
The Journal of Practical Medicine
基金
广东省自然科学基金项目(编号:2016A030313654)。
关键词
急性淋巴细胞白血病
免疫疗法
儿童
抗体
嵌合抗原受体
acute lymphoblastic leukemia
immunotherapy
children
antibody
chimeric antigen receptor
